Skip to main content

Month: April 2025

Astec Reports First Quarter 2025 Results, Enters Into Definitive Agreement to Acquire TerraSource Holdings, LLC

First Quarter 2025 Overview (all comparisons are made to the corresponding prior year first quarter unless otherwise specified):Net sales of $329.4 million Strong net income of $14.3 million; Adjusted net income of $20.3 million EBITDA of $27.5 million; Adjusted EBITDA of $35.2 million Diluted EPS of $0.62; Adjusted EPS of $0.88 Operating cash flow of $20.5 million; Free cash flow of $16.6 million Entered definitive purchase agreement to acquire TerraSource Holdings, LLC (“TerraSource”) for $245.0 millionCHATTANOOGA, Tenn., April 29, 2025 (GLOBE NEWSWIRE) — Astec Industries, Inc. (Nasdaq: ASTE) announced today its financial results for the first quarter ended March 31, 2025. “We are pleased to report another strong quarter in line with our plans to deliver consistency, profitability and growth,” said...

Continue reading

Regeneron Reports First Quarter 2025 Financial and Operating Results

First quarter 2025 revenues of $3.0 billion; GAAP diluted EPS of $7.27 and non-GAAP diluted EPS(a) of $8.22 First quarter 2025 Dupixent® global net sales (recorded by Sanofi) increased 19% to $3.67 billion versus first quarter 2024 First quarter 2025 EYLEA HD® U.S. net sales increased 54% to $307 million versus first quarter 2024; total EYLEA HD and EYLEA® U.S. net sales decreased 26% to $1.04 billion Dupixent approved for chronic spontaneous urticaria (CSU) in U.S.; approved for chronic obstructive pulmonary disease (COPD) in Japan FDA accepted for priority review EYLEA HD sBLA for both retinal vein occlusion (RVO) and for monthly dosing in approved indications; update provided on FDA review of EYLEA HD pre-filled syringe submission Lynozyfic™ (linvoseltamab) approved in EU for relapsed/refractory multiple myeloma Regulatory...

Continue reading

HighPeak Energy, Inc. Announces 2025 First Quarter Earnings Release and Conference Call Dates

FORT WORTH, Texas, April 29, 2025 (GLOBE NEWSWIRE) — HighPeak Energy, Inc. (NASDAQ: HPK) (“HighPeak Energy”), today announced that it plans to release its 2025 first quarter financial and operating results after the close of trading on Monday, May 12, 2025. HighPeak Energy will host a conference call and webcast on Tuesday, May 13, 2025 at 10:00 a.m. Central Time for investors and analysts to discuss its 2025 first quarter financial results and operational highlights. Participants may register for the call here. Access to the live audio-only webcast and replay of the earnings release conference call may be found here. A live broadcast of the earnings conference call will also be available on HighPeak Energy’s website at www.highpeakenergy.com under the “Investors” section of the website.   About HighPeak Energy, Inc. HighPeak Energy...

Continue reading

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company’s investor website approximately two hours after the call’s conclusion. Participants are advised to join 15 minutes prior to the start time. About Biodesix Biodesix is a leading diagnostic solutions...

Continue reading

Dogecoin Cash, Inc. Name Change Finalized and Reflected on U.S. Markets Following FINRA Notification

Company Confirms Completion of Name Change as Disclosed in Recent SEC Filing Mesquite, April 29, 2025 (GLOBE NEWSWIRE) — Mesquite, Nevada — April 29, 2025 — Dogecoin Cash, Inc. (OTC: CBDS) today announced that its corporate name change has been finalized and is now reflected across U.S. stock market systems, following notification from the Financial Industry Regulatory Authority (FINRA). The name change was authorized through the filing of a Certificate of Amendment to the Company’s Articles of Incorporation with the Nevada Secretary of State on November 13, 2024, and became market effective on April 25, 2025, following FINRA’s completion of its processing. This update aligns with the Company’s previously reported disclosures, including the filing of a Current Report on Form 8-K with the Securities and Exchange Commission on April...

Continue reading

Ambow Launches HybriU Conferencing: A Next-Gen Platform for Smart, Seamless Phygital (Physical + Digital) Collaboration

Cupertino, Calif, April 29, 2025 (GLOBE NEWSWIRE) — Ambow Education Holding Ltd. (NYSE American: AMBO) (“Ambow” or the “Company”), a leading global EdTech and AI-powered solutions provider, today announced the official launch of HybriU Conferencing, a cutting-edge platform designed to transform traditional conferencing into smart, seamless Phygital (Physical + Digital) experiences. HybriU Conferencing blends the strengths of in-person presence with advanced digital intelligence, enabling organizations to host immersive, AI-enhanced conferences, meetings and collaborative sessions. Key features include real-time transcription, multilingual translation, 3D telepresence and adaptive screen layouts — delivering a frictionless hybrid experience for both on-site and remote participants. “HybriU Conferencing marks a major leap forward...

Continue reading

Charging Robotics: Revoltz Secures First Institutional Client for PORTO EV Logistics Deployment

Marks Expansion Beyond Individual Customers into Fleet and Commercial Applications Tel Aviv, Israel, April 29, 2025 (GLOBE NEWSWIRE) — Charging Robotics Inc. (OTC: CHEV), announced today that its affiliate, Revoltz Ltd. (of which Charging Robotics owns 19.9%), has secured its first institutional client for the PORTO EV, Revoltz’s flagship electric micro-vehicle designed for last-mile logistics. The new order marks a significant step in Revoltz’s commercial expansion strategy, transitioning from individual sales into larger fleet deployments. The institutional customer — a prominent logistics provider — will integrate PORTO EVs into its urban delivery fleet, reinforcing the growing demand for sustainable, compact electric mobility solutions across commercial operations. “This first institutional order validates our vision to transform...

Continue reading

U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

– ZEVASKYN fills a critical need for people living with RDEB, a debilitating dermatological condition with no cure – – Approval based on the pivotal Phase 3 VIITAL™ study, showing ZEVASKYN resulted in significant wound healing and pain reduction after a single treatment with a favorable safety profile – – ZEVASKYN to be available through Qualified Treatment Centers beginning in 3Q 2025 – – Abeona Assist™ patient services program offers personalized support for eligible patients and families throughout their treatment journey with ZEVASKYN – – Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA – – Abeona Therapeutics® to host conference call today, Tuesday, April 29, 2025, at 8:00 a.m. ET – CLEVELAND, April 29, 2025 (GLOBE NEWSWIRE)...

Continue reading

Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. “The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”) continues to accelerate, with 95% net sales growth in the first quarter versus the fourth quarter of 2024, driven by significant...

Continue reading

AgEagle Aerial Systems Receives Non-Compliance Notice from NYSE American and Makes NYSE American Section 610(b) Public Announcement

WICHITA, Kan., April 29, 2025 (GLOBE NEWSWIRE) — AgEagle Aerial Systems Inc. (NYSE: UAVS) a leading provider of best-in-class unmanned aerial systems (UAS), sensors and software solutions for customers worldwide in the commercial and government verticals, announces that on April 23, 2025, the Company received written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) requiring stockholders’ equity of (i) $2.0 million or more if the Company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, (ii) $4.0 million or more if the Company has reported losses...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.